Trial Profile
A randomised, double-blind, placebo-controlled, 2-period crossover study to evaluate effects of multiple oral doses of S-555739 on nasal allergen challenge in subjects with intermittent grass pollen sensitive allergic rhinitis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Asapiprant (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Shionogi
- 01 Apr 2022 Status changed from recruiting to completed.
- 29 Jul 2011 New trial record